"10.1371_journal.pone.0140782","plos one","2015-10-16T00:00:00Z","Jos√© Manuel Molina-Guijarro; Carolina Garc√≠a; √Ålvaro Mac√≠as; Luis Francisco Garc√≠a-Fern√°ndez; Cristina Moreno; Fernando Reyes; Juan Fernando Mart√≠nez-Leal; Rogelio Fern√°ndez; Valent√≠n Mart√≠nez; Carmen Valenzuela; M Pilar Lillo; Carlos M Galmarini","Departamento de Investigaci√≥n y Desarrollo, PharmaMar S.A., Colmenar Viejo, Madrid, Spain; Departamento de Qu√≠mica F√≠sica Biol√≥gica, Instituto de Qu√≠mica-F√≠sica ‚ÄúRocasolano‚Äù (CSIC), Madrid, Spain; Instituto de Investigaciones Biom√©dicas ‚ÄúAlberto Sols‚Äù (CSIC-UAM), Madrid, Spain; Fundaci√≥n MEDINA, Parque Tecnol√≥gico de Ciencias de la Salud, Armilla, Granada, Spain","Conceived and designed the experiments: JMMG LFGF FR CV MPL CMG. Performed the experiments: JMMG CG AM CM RF VM MPL. Analyzed the data: JMMG CG AM LFGF CM FR JFML RF VM CV MPL CMG. Contributed reagents/materials/analysis tools: JMMG CG AM LFGF CM FR JFML RF VM CV MPL CMG. Wrote the paper: JMMG CV MPL CMG.","The authors of this manuscript have read the journals policy and have the following competing interests: Jos√© Manuel Molina-Guijarro, Luis Francisco Garc√≠a-Fern√°ndez, Juan Fernando Mart√≠nez-Leal, Rogelio Fern√°ndez, Valent√≠n Mart√≠nez, and Carlos M. Galmarini are employees and shareholders of PharmaMar S.A. Actual patent application of elisidepsin belongs to PharmaMar SA. There are no products in development or marketed products to declare. This does not alter the authors‚Äô adherence to PLOS ONE policies on sharing data and materials.","2015","10","Jos√© Manuel Molina-Guijarro","J√MMG",12,TRUE,6,7,12,4,TRUE,TRUE,TRUE,1,"3",FALSE
